Abstract |
Outpatient terminations were performed on 100 ultrasonographically confirmed pregnancies of less than or equal to 63 days with a single oral dose of RU 38,486 (600 mg) and a single vaginal pessary of 16,16-dimethyl-trans-delta 2-prostaglandin E1 (1 mg) 48 hours later. Abortion occurred in all patients; in 95 it was complete, in four it was incomplete, and one resulted in a missed abortion. In 88% the abortion occurred within 4 hours of prostaglandin treatment. A total of 25% of patients had nausea and 15% vomited after RU 38,486 treatment. After prostaglandin-treatment, 13% vomited, 10% had diarrhea, and 23% required administration of an opiate analgesic agent. No patient was transfused and there was no genital tract trauma; one case of suspected pelvic infection occurred. If the need for termination arose again, 88% would elect to use the method again, 9% would not. The combination of the antiprogestin RU 38,486 and a vaginal prostaglandin pessary appears to offer a safe, efficient, acceptable nonsurgical outpatient method of termination. Further studies on dosage and treatment protocols would be justified.
|
Authors | N C Hill, J Ferguson, I Z MacKenzie |
Journal | American journal of obstetrics and gynecology
(Am J Obstet Gynecol)
Vol. 162
Issue 2
Pg. 414-7
(Feb 1990)
ISSN: 0002-9378 [Print] United States |
PMID | 1689961
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Abortifacient Agents
- Abortifacient Agents, Nonsteroidal
- Chorionic Gonadotropin
- Chorionic Gonadotropin, beta Subunit, Human
- Peptide Fragments
- Mifepristone
- gemeprost
- Alprostadil
|
Topics |
- Abortifacient Agents
(administration & dosage)
- Abortifacient Agents, Nonsteroidal
(administration & dosage)
- Abortion, Induced
(methods)
- Administration, Oral
- Adult
- Alprostadil
(administration & dosage, adverse effects, analogs & derivatives)
- Chorionic Gonadotropin
(blood)
- Chorionic Gonadotropin, beta Subunit, Human
- Female
- Follow-Up Studies
- Humans
- Mifepristone
(administration & dosage, adverse effects)
- Patient Acceptance of Health Care
- Peptide Fragments
(blood)
- Pessaries
- Pregnancy
- Pregnancy Trimester, First
|